Phase I/II Trial of Ipilimumab (Immunotherapy) and Hypofractionated Stereotatic Radiation Therapy in Patients with Advanced Solid Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Ipilimumab (Primary)
- Indications Adrenal cancer; Liver cancer; Lung cancer
- Focus Adverse reactions
- 20 Jun 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 20 Jun 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
- 20 Sep 2016 Results from Phase I part of this trial (n=35) published in the Clinical cancer research: an official journal of the American Association for Cancer Research